journal
MENU ▼
Read by QxMD icon Read
search

Liver Cancer

journal
https://read.qxmd.com/read/30488024/no-muscle-depletion-with-high-visceral-fat-as-a-novel-beneficial-biomarker-of-sorafenib-for-hepatocellular-carcinoma
#1
Issei Saeki, Takahiro Yamasaki, Masaki Maeda, Reo Kawano, Takuro Hisanaga, Takuya Iwamoto, Toshihiko Matsumoto, Isao Hidaka, Tsuyoshi Ishikawa, Taro Takami, Isao Sakaida
Background: Sorafenib is a standard therapy for patients with advanced hepatocellular carcinoma (HCC). However, no predictive biomarkers of sorafenib efficacy have been discovered. Herein, we investigated the impact of body composition, such as skeletal muscle and visceral fat, on the prognosis of advanced HCC patients treated with sorafenib. Methods: We enrolled 100 patients with advanced HCC treated with sorafenib. Prior to receiving sorafenib therapy, skeletal muscle index (SMI) and visceral fat area (VFA) were measured using computed tomography at the third lumbar vertebra and umbilical level, respectively...
October 2018: Liver Cancer
https://read.qxmd.com/read/30488023/the-prognosis-of-single-large-hepatocellular-carcinoma-was-distinct-from-barcelona-clinic-liver-cancer-stage-a-or-b-the-role-of-albumin-bilirubin-grade
#2
Kuan-Chieh Fang, Wei-Yu Kao, Chien-Wei Su, Po-Chun Chen, Pei-Chang Lee, Yi-Hsiang Huang, Teh-Ia Huo, Chun-Chao Chang, Ming-Chih Hou, Han-Chieh Lin, Jaw-Ching Wu
Background/Aims: Whether single large hepatocellular carcinoma (SLHCC) is classified as Barcelona Clinic Liver Cancer (BCLC) stage A or B is still controversial. We aimed to compare the clinical manifestations, treatment modalities, and prognoses among patients with SLHCC and those in BCLC stage A and B. Methods: We enrolled 2,285 treatment-naive hepatocellular carcinoma (HCC) patients with BCLC stage A or B from October 2007 to December 2015. Factors in terms of prognoses were analyzed by multivariate analysis...
October 2018: Liver Cancer
https://read.qxmd.com/read/30488022/effectiveness-of-particle-radiotherapy-in-various-stages-of-hepatocellular-carcinoma-a-pilot-study
#3
Yushi Sorin, Kenji Ikeda, Yusuke Kawamura, Shunichiro Fujiyama, Masahiro Kobayashi, Tetsuya Hosaka, Hitomi Sezaki, Norio Akuta, Satoshi Saitoh, Fumitaka Suzuki, Yoshiyuki Suzuki, Yasuji Arase, Hiromitsu Kumada
Aim: We analyzed the effectiveness of external particle radiotherapy (PRT) as an alternative therapy for various stages of hepatocellular carcinoma (HCC). Methods: Eighty-three patients with HCC underwent PRT in our hospital from 2007 to 2015 (proton beam radiation in 58 patients and carbon ion radiation in 25 patients), including patients with early-stage HCC (single HCC measuring ≤3 cm, Barcelona Clinic Liver Cancer [BCLC] stage 0 or A) (group A, n = 30), those with intermediate-stage HCC (HCCs measuring ≥3 cm but inoperable or multinodular and transcatheter arterial embolization [TACE]-refractory, BCLC stage B) (group B, n = 31), and those with advanced-stage HCC (HCC with portal invasion or extrahepatic metastasis) (group C, n = 22)...
October 2018: Liver Cancer
https://read.qxmd.com/read/30488021/multidisciplinary-taiwan-consensus-recommendations-for-the-use-of-debdox-tace-in-hepatocellular-carcinoma-treatment
#4
Pi-Yi Chang, Chun-Chieh Huang, Chao-Hung Hung, Chih-Yung Yu, Ding-Kwo Wu, Jen-I Hwang, Po-Chin Liang, Reng-Hong Wu, Wei-Lun Tsai, Yih-Jyh Lin, Yi-Sheng Liu, Huei-Lung Liang, Rheun-Chuan Lee, Chien-Hung Chen
Transarterial chemoembolization (TACE) is the first-line treatment in patients with unresectable hepatocellular carcinoma (HCC). In recent years, there has been increasing clinical evidence that drug-eluting beads provide a combined ischemic and cytotoxic effect that may be superior to conventional TACE, with low systemic toxicity. The therapeutic value of TACE performed using the embolic microsphere DC Bead loaded with doxorubicin (drug-eluting bead doxorubicin [DEBDOX]) has been shown by several randomized controlled trials...
October 2018: Liver Cancer
https://read.qxmd.com/read/30488020/ramucirumab-as-second-line-systemic-therapy-in-hepatocellular-carcinoma
#5
EDITORIAL
Masatoshi Kudo
No abstract text is available yet for this article.
October 2018: Liver Cancer
https://read.qxmd.com/read/30319990/response-to-the-comments-on-cicalese-et-al-an-ecological-study-of-the-association-between-air-pollution-and-hepatocellular-carcinoma-incidence-in-texas
#6
Loren Raun, Ali Shirafkan, Laura Campos, Daria Zorzi, Mauro Montalbano, Colin Rhoads, Valia Gazis, Katherine Ensor, Cristiana Rastellini, Luca Cicalese
No abstract text is available yet for this article.
September 2018: Liver Cancer
https://read.qxmd.com/read/30319989/methodological-limitations-to-the-analysis-by-cicalese-et-al
#7
Gary M Marsh, Kevin M Towle
No abstract text is available yet for this article.
September 2018: Liver Cancer
https://read.qxmd.com/read/30319988/european-council-of-vinyl-manufacturers-comments-on-cicalese-et-al-an-ecological-study-of-the-association-between-air-pollution-and-hepatocellular-carcinoma-incidence-in-texas
#8
Ariane Gennissen, Marc Boeckx, Arjen Sevenster
No abstract text is available yet for this article.
September 2018: Liver Cancer
https://read.qxmd.com/read/30319987/vinyl-institute-comments-on-cicalese-et-al-an-ecological-study-of-the-association-between-air-pollution-and-hepatocellular-carcinoma-incidence-in-texas
#9
https://read.qxmd.com/read/30319986/erratum
#10
(no author information available yet)
[This corrects the article DOI: 10.1159/000481416.].
September 2018: Liver Cancer
https://read.qxmd.com/read/30319985/immune-gene-expression-profile-in-hepatocellular-carcinoma-and-surrounding-tissue-predicts-time-to-tumor-recurrence
#11
Chiara Carone, Andrea Olivani, Raffaele Dalla Valle, Roberta Manuguerra, Enrico Maria Silini, Tommaso Trenti, Gabriele Missale, Elisabetta Cariani
Background: The antitumor immune response may play a major role in the clinical outcome of hepatocellular carcinoma (HCC). We characterized the liver immune microenvironment by direct hybridization of RNA extracted from HCC and nontumorous tissues. Methods: RNA was extracted from frozen liver tissue samples of HCC (T; n = 30) and nontumorous tissues (NT; n = 33) obtained from 38 patients. Matched samples were available for 25 patients. The immune gene expression profile was analyzed with the nCounter GX Human Immunology v2 system (NanoString Technologies), which detects the expression levels of 579 immune response-related genes simultaneously...
September 2018: Liver Cancer
https://read.qxmd.com/read/30319984/long-term-prognostic-factors-after-hepatic-resection-for-hepatitis-c-virus-related-hepatocellular-carcinoma-with-a-special-reference-to-viral-status
#12
Masaki Koda, Shogo Tanaka, Shigekazu Takemura, Hiroji Shinkawa, Masahiko Kinoshita, Genya Hamano, Tokuji Ito, Norifumi Kawada, Toshihiko Shibata, Shoji Kubo
Background: Although studies have reported on long-term (10-year) survival after hepatic resection for hepatocellular carcinoma (HCC), they did not focus on patients with hepatitis C virus (HCV)-related HCC, and the contribution of antiviral therapy to long-term survival (especially ≥15 years) has not been adequately examined. We investigated the long-term outcome after hepatic resection for HCV-related HCC, including the effects of interferon (IFN) therapy, and the changes in prognostic factors according to postoperative duration...
September 2018: Liver Cancer
https://read.qxmd.com/read/30319983/guidelines-for-diagnosis-and-treatment-of-primary-liver-cancer-in-china-2017-edition
#13
Jian Zhou, Hui-Chuan Sun, Zheng Wang, Wen-Ming Cong, Jian-Hua Wang, Meng-Su Zeng, Jia-Mei Yang, Ping Bie, Lian-Xin Liu, Tian-Fu Wen, Guo-Hong Han, Mao-Qiang Wang, Rui-Bao Liu, Li-Gong Lu, Zheng-Gang Ren, Min-Shan Chen, Zhao-Chong Zeng, Ping Liang, Chang-Hong Liang, Min Chen, Fu-Hua Yan, Wen-Ping Wang, Yuan Ji, Wen-Wu Cheng, Chao-Liu Dai, Wei-Dong Jia, Ya-Ming Li, Ye-Xiong Li, Jun Liang, Tian-Shu Liu, Guo-Yue Lv, Yi-Lei Mao, Wei-Xin Ren, Hong-Cheng Shi, Wen-Tao Wang, Xiao-Ying Wang, Bao-Cai Xing, Jian-Ming Xu, Jian-Yong Yang, Ye-Fa Yang, Sheng-Long Ye, Zheng-Yu Yin, Bo-Heng Zhang, Shui-Jun Zhang, Wei-Ping Zhou, Ji-Ye Zhu, Rong Liu, Ying-Hong Shi, Yong-Sheng Xiao, Zhi Dai, Gao-Jun Teng, Jian-Qiang Cai, Wei-Lin Wang, Jia-Hong Dong, Qiang Li, Feng Shen, Shu-Kui Qin, Jia Fan
Background: Hepatocellular carcinoma (HCC) (about 85-90% of primary liver cancer) is particularly prevalent in China because of the high prevalence of chronic hepatitis B infection. HCC is the fourth most common malignancy and the third leading cause of tumor-related deaths in China. It poses a significant threat to the life and health of Chinese people. Summary: This guideline presents official recommendations of the National Health and Family Planning Commission of the People's Republic of China on the surveillance, diagnosis, staging, and treatment of HCC occurring in China...
September 2018: Liver Cancer
https://read.qxmd.com/read/30319982/proposal-of-primary-endpoints-for-tace-combination-trials-with-systemic-therapy-lessons-learned-from-5-negative-trials-and-the-positive-tactics-trial
#14
EDITORIAL
https://read.qxmd.com/read/30319981/extremely-high-objective-response-rate-of-lenvatinib-its-clinical-relevance-and-changing-the-treatment-paradigm-in-hepatocellular-carcinoma
#15
EDITORIAL
https://read.qxmd.com/read/29888210/hepatic-arterial-infusion-chemotherapy-a-potential-therapeutic-option-for-hepatocellular-carcinoma-with-portal-vein-tumor-thrombus
#16
Michihisa Moriguchi, Takeshi Aramaki, Toshihiro Tanaka, Yoshito Itoh
No abstract text is available yet for this article.
May 2018: Liver Cancer
https://read.qxmd.com/read/29888209/successful-hepatic-arterial-infusion-of-chemotherapy-in-a-patient-with-advanced-hepatocellular-carcinoma-and-impending-liver-failure
#17
Tsung-Hao Liu, Chih-Hung Hsu, Yu-Yun Shao
No abstract text is available yet for this article.
May 2018: Liver Cancer
https://read.qxmd.com/read/29888208/risk-of-de-novo-hepatocellular-carcinoma-after-hcv-treatment-with-direct-acting-antivirals
#18
Fabian Finkelmeier, Georg Dultz, Kai-Henrik Peiffer, Bernd Kronenberger, Franziska Krauss, Stefan Zeuzem, Christoph Sarrazin, Johannes Vermehren, Oliver Waidmann
Background and Aims: The aim of the study was to evaluate the risk of hepatocellular carcinoma (HCC) development after treatment with direct-acting antivirals (DAAs) and to compare HCC occurrence in these patients with that among patients treated with interferon (IFN)-based therapies. Methods: We analyzed a large cohort with chronic hepatitis C virus patients for the onset of new HCC after DAA treatment. A historical IFN-treated cohort was investigated for comparison...
May 2018: Liver Cancer
https://read.qxmd.com/read/29888207/liver-transplantation-for-intermediate-stage-hepatocellular-carcinoma
#19
Naoko Kamo, Toshimi Kaido, Shintaro Yagi, Hideaki Okajima, Shinji Uemoto
Transarterial chemoembolization is the standard treatment for patients with intermediate-stage hepatocellular carcinoma (HCC) according to the Barcelona Clinic Liver Cancer staging system. However, in Japan, not a few patients with intermediate-stage HCC undergo liver transplantation (LT). The present study investigated characteristics and outcomes of LT for intermediate-stage HCC. Between February 1999 and November 2016, a total of 226 patients underwent LT for HCC at our institute. Among these, 56 patients showed intermediate-stage HCC (24...
May 2018: Liver Cancer
https://read.qxmd.com/read/29888206/a-phase-i-randomized-phase-ii-study-to-evaluate-the-safety-pharmacokinetics-and-efficacy-of-nintedanib-versus-sorafenib-in-asian-patients-with-advanced-hepatocellular-carcinoma
#20
Chia-Jui Yen, Tae-You Kim, Yin-Hsun Feng, Yee Chao, Deng-Yn Lin, Baek-Yeol Ryoo, Dennis Chin-Lun Huang, David Schnell, Julia Hocke, Arsène-Bienvenu Loembé, Ann-Lii Cheng
Background: Nintedanib is an oral, triple angiokinase inhibitor of vascular endothelial growth factor/platelet-derived growth factor/fibroblast growth factor receptors. This randomized, multicenter, open-label, phase I/II study evaluated the safety, pharmacokinetics, maximum tolerated dose (MTD) in terms of dose-limiting toxicities (DLTs), and efficacy of nintedanib versus sorafenib in Asian patients with unresectable advanced hepatocellular carcinoma (HCC). Patients and Methods: For the phase I portion, patients were stratified into two groups according to their alanine aminotransferase/aspartate aminotransferase (ALT/AST) and Child-Pugh score at baseline...
May 2018: Liver Cancer
journal
journal
47850
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"